Exclusive special offer and discount title banner vector image

GLOBAL INFECTIOUS LARYNGOTRACHEITIS DISEASE VACCINE MARKET FORECAST 2023-2032

SCOPE OF THE REPORT


MARKET OVERVIEW

The global infectious laryngotracheitis disease vaccine market was valued at $25.84 million in 2022 and is expected to reach $58.07 million by 2032, growing at a CAGR of 8.42% during the forecast period, 2023 to 2032. The base year considered for the market study is 2022, and the estimated period is between 2023 and 2032. 

The respiratory illness avian infectious laryngotracheitis (ILT) is caused by a herpesvirus called Gallid alpha herpesvirus type 1 (GaHV-1) or infectious laryngotracheitis virus (ILTV). Although it is mostly an illness observed in chickens, it can also infect pheasants, partridges, and peafowl. Clinically, the condition can manifest itself in three ways: acute, subacute, and chronic or mild. Furthermore, infectious laryngotracheitis (ILT) disease vaccines are produced through live attenuated vaccines. Each dose comprises a freeze-dried chicken embryo propagated culture of the infectious laryngotracheitis virus’ altered strain.

GLOBAL-INFECTIOUS-LARYNGOTRACHEITIS-DISEASE-VACCINE-MARKET

Read our latest blog on the Poultry Disease Vaccine Market

GROWTH ENABLERS

Key enablers of the global infectious laryngotracheitis disease vaccine market growth: 

  • Globalization of poultry trade
    • Infectious laryngotracheitis is a disease that can be spread due to the globalization of the chicken trade; it affects both domestic and wild birds. The infection can also be transmitted through direct contact with affected birds or contaminated equipment, feed, and water. 
    • During cross-border poultry trade, there is a high risk that the disease could spread to other areas, resulting in major outbreaks and significant economic losses.
  • Rising awareness of disease prevention
  • Lack of biosecurity resulting in transmission of diseases
  • Technological advancements in vaccine development
  • Government policies to control infectious laryngotracheitis disease

GROWTH RESTRAINTS

Key growth restraining factors of the global infectious laryngotracheitis disease vaccine market:

  • Vaccine efficacy and safety concerns
  • Lack of monetary feasibility to develop rare disease drugs
    • The drug development process is an immensely capital-intensive and time-consuming procedure, necessitating investments amounting to billions of dollars for extensive research, rigorous testing, and the subsequent marketing of the drug. 
    • Given that the occurrence of infectious laryngotracheitis disease is exceedingly rare on a global scale, there is a lack of financial incentive and potential profitability in the realm of developing vaccines specifically tailored for the infectious laryngotracheitis disease vaccine market.

To Know More About This Report, Request a Free Sample Copy

DISEASE OVERVIEW

Global Infectious Laryngotracheitis Disease Vaccine Market | Disease Overview

  • Introduction
  • Symptoms
    • Infectious laryngotracheitis disease symptoms include vision impairment, reduction in feed consumption, sudden drop in egg production, sneezing, swelling of eyelids and face, discharges from the nose or eyes, coughing, gurgling sounds (rales) and coughing blood or blood-stained mucus, difficulty breathing (open-beak breathing as well as gasping for air with neck extension) due to obstruction of the trachea and larynx.
  • Causes
  • Diagnosis
    • PCR and histopathology of the trachea and conjunctiva is the common method of diagnosis. PCR and histopathology of the trachea and conjunctiva is the common method of diagnosis. Rapid ILT diagnosis techniques involve immunofluorescence on tracheal exudate or frozen sections as well as an enzyme-linked immunosorbent assay (ELISA) to detect viral antigens in mucosal scrapings. 
    • Polymerase chain reaction (PCR) methods have been proven to be more sensitive than virus isolation in analyzing clinical material and are now commonly used. Both traditional and real-time PCR approaches are utilized to detect ILT virus DNA.
  • Treatment

GEOGRAPHICAL STUDY

Geographical Study based on Four Major Regions:

  • North America: The United States and Canada
    • North America is the largest market for the ILT disease vaccine market.
    • The region experiences a high demand for poultry products and meat. Thus, vaccination of livestock is required to prevent the onset of poultry diseases. 
    • The United States government allocates substantial funding for research and production of new vaccines. In addition, the country is one of the largest exporters of poultry products, as well. 
    • North America is also home to major companies in the poultry disease vaccine market, namely Zoetis, Elanco Animal Health, Merck Animal Health, etc.
  • Europe: The United Kingdom, Germany, France, Italy, Belgium, Poland, and Rest of Europe
  • Asia-Pacific: China, Japan, India, South Korea, Australia & New Zealand, and Rest of Asia-Pacific
  • Rest of World: Latin America, the Middle East & Africa

MAJOR PLAYERS

Major players in the global infectious laryngotracheitis disease vaccine market:

  • Zoetis
  • Merck Animal Health
  • Ceva Animal Health
  • Boehringer Ingelheim
  • Elanco Animal Health

REPORT SYNOPSIS

REPORT SCOPEDETAILS
Market Forecast Years2023-2032
Base Year2022
Market Historical Years2018-2022
Forecast UnitsRevenue ($ Million)
Geographies AnalyzedNorth America, Europe, Asia-Pacific, and Rest of World
Companies AnalyzedZoetis, Merck Animal Health, Ceva Animal Health, Boehringer Ingelheim, Elanco Animal Health, HIPRA

TABLE OF CONTENT

  1. RESEARCH SCOPE & METHODOLOGY
    1. STUDY OBJECTIVES
    2. SCOPE OF STUDY
    3. METHODOLOGY
    4. ASSUMPTIONS & LIMITATIONS
  2. EXECUTIVE SUMMARY 
    1. MARKET SIZE & ESTIMATES
    2. MARKET SNAPSHOT
  3. DISEASE OVERVIEW
    1. INTRODUCTION
    2. SYMPTOMS
    3. CAUSES
    4. DIAGNOSIS
    5. TREATMENT
  4. MARKET DYNAMICS
    1. DRIVERS
      1. GLOBALIZATION OF POULTRY TRADE
      2. RISING AWARENESS OF DISEASE PREVENTION
      3. LACK OF BIOSECURITY RESULTING IN TRANSMISSION OF DISEASES
      4. TECHNOLOGICAL ADVANCEMENTS IN VACCINE DEVELOPMENT
      5. GOVERNMENT POLICIES TO CONTROL INFECTIOUS LARYNGOTRACHEITIS DISEASE 
    2. RESTRAINTS
      1. VACCINE EFFICACY AND SAFETY CONCERNS
      2. LACK OF MONETARY FEASIBILITY TO DEVELOP RARE DISEASE DRUGS
  5. INFECTIOUS LARYNGOTRACHEITIS DISEASE VACCINE PIPELINE ANALYSIS
    1. ANALYSIS BY CANDIDATE
    2. ANALYSIS BY DEVELOPMENT APPROACH
    3. ANALYSIS BY PHASE
    4. DRUG PROFILING
    5. TYPES OF VACCINES FOR INFECTIOUS LARYNGOTRACHEITIS DISEASE
  6. GEOGRAPHICAL ANALYSIS
    1. NORTH AMERICA
      1. MARKET SIZE & ESTIMATES
      2. REGIONAL OVERVIEW
      3. COUNTRY ANALYSIS
        1. UNITED STATES
        2. CANADA
    2. EUROPE
      1. MARKET SIZE & ESTIMATES
      2. REGIONAL OVERVIEW
      3. COUNTRY ANALYSIS
        1. UNITED KINGDOM
        2. GERMANY
        3. FRANCE
        4. ITALY
        5. BELGIUM
        6. POLAND
        7. REST OF EUROPE
    3. ASIA-PACIFIC
      1. MARKET SIZE & ESTIMATES
      2. REGIONAL OVERVIEW
      3. COUNTRY ANALYSIS
        1. CHINA
        2. JAPAN
        3. INDIA
        4. SOUTH KOREA
        5. AUSTRALIA & NEW ZEALAND
        6. REST OF ASIA-PACIFIC
    4. REST OF WORLD
      1. MARKET SIZE & ESTIMATES
      2. REGIONAL OVERVIEW
      3. REGIONAL ANALYSIS
        1. LATIN AMERICA
        2. MIDDLE EAST & AFRICA
  7. COMPETITIVE LANDSCAPE
    1. COMPANY PROFILES
      1. BOEHRINGER INGELHEIM
      2. CEVA ANIMAL HEALTH
      3. ELANCO ANIMAL HEALTH
      4. HIPRA
      5. MERCK ANIMAL HEALTH
      6. ZOETIS

LIST OF TABLES

TABLE 1: MARKET SNAPSHOT – INFECTIOUS LARYNGOTRACHEITIS DISEASE VACCINE

TABLE 2: GLOBAL INFECTIOUS LARYNGOTRACHEITIS DISEASE VACCINE MARKET, BY GEOGRAPHY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 3: GLOBAL INFECTIOUS LARYNGOTRACHEITIS DISEASE VACCINE MARKET, BY GEOGRAPHY, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 4: NORTH AMERICA INFECTIOUS LARYNGOTRACHEITIS DISEASE VACCINE MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 5: NORTH AMERICA INFECTIOUS LARYNGOTRACHEITIS DISEASE VACCINE MARKET, BY COUNTRY, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 6: EUROPE INFECTIOUS LARYNGOTRACHEITIS DISEASE VACCINE MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 7: EUROPE INFECTIOUS LARYNGOTRACHEITIS DISEASE VACCINE MARKET, BY COUNTRY, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 8: ASIA-PACIFIC INFECTIOUS LARYNGOTRACHEITIS DISEASE VACCINE MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 9: ASIA-PACIFIC INFECTIOUS LARYNGOTRACHEITIS DISEASE VACCINE MARKET, BY COUNTRY, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 10: REST OF WORLD INFECTIOUS LARYNGOTRACHEITIS DISEASE VACCINE MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 11: REST OF WORLD INFECTIOUS LARYNGOTRACHEITIS DISEASE VACCINE MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)

LIST OF FIGURES

FIGURE 1: NORTH AMERICA INFECTIOUS LARYNGOTRACHEITIS DISEASE VACCINE MARKET, COUNTRY OUTLOOK, 2022 & 2032 (IN %)

FIGURE 2: UNITED STATES INFECTIOUS LARYNGOTRACHEITIS DISEASE VACCINE MARKET, 2023-2032 (IN $ MILLION)

FIGURE 3: CANADA INFECTIOUS LARYNGOTRACHEITIS DISEASE VACCINE MARKET, 2023-2032 (IN $ MILLION)

FIGURE 4: EUROPE INFECTIOUS LARYNGOTRACHEITIS DISEASE VACCINE MARKET, COUNTRY OUTLOOK, 2022 & 2032 (IN %)

FIGURE 5: UNITED KINGDOM INFECTIOUS LARYNGOTRACHEITIS DISEASE VACCINE MARKET 2023-2032 (IN $ MILLION)

FIGURE 6: GERMANY INFECTIOUS LARYNGOTRACHEITIS DISEASE VACCINE MARKET 2023-2032 (IN $ MILLION)

FIGURE 7: FRANCE INFECTIOUS LARYNGOTRACHEITIS DISEASE VACCINE MARKET 2023-2032 (IN $ MILLION)

FIGURE 8: ITALY INFECTIOUS LARYNGOTRACHEITIS DISEASE VACCINE MARKET 2023-2032 (IN $ MILLION)

FIGURE 9: BELGIUM INFECTIOUS LARYNGOTRACHEITIS DISEASE VACCINE MARKET 2023-2032 (IN $ MILLION)

FIGURE 10: POLAND INFECTIOUS LARYNGOTRACHEITIS DISEASE VACCINE MARKET 2023-2032 (IN $ MILLION)

FIGURE 11: REST OF EUROPE INFECTIOUS LARYNGOTRACHEITIS DISEASE VACCINE MARKET 2023-2032 (IN $ MILLION)

FIGURE 12: ASIA-PACIFIC INFECTIOUS LARYNGOTRACHEITIS DISEASE VACCINE MARKET, COUNTRY OUTLOOK, 2022 & 2032 (IN %)

FIGURE 13: CHINA INFECTIOUS LARYNGOTRACHEITIS DISEASE VACCINE MARKET, 2023-2032 (IN $ MILLION)

FIGURE 14: JAPAN INFECTIOUS LARYNGOTRACHEITIS DISEASE VACCINE MARKET, 2023-2032 (IN $ MILLION)

FIGURE 15: INDIA INFECTIOUS LARYNGOTRACHEITIS DISEASE VACCINE MARKET, 2023-2032 (IN $ MILLION)

FIGURE 16: SOUTH KOREA INFECTIOUS LARYNGOTRACHEITIS DISEASE VACCINE MARKET, 2023-2032 (IN $ MILLION)

FIGURE 17: AUSTRALIA & NEW ZEALAND INFECTIOUS LARYNGOTRACHEITIS DISEASE VACCINE MARKET, 2023-2032 (IN $ MILLION)

FIGURE 18: REST OF ASIA-PACIFIC INFECTIOUS LARYNGOTRACHEITIS DISEASE VACCINE MARKET, 2023-2032 (IN $ MILLION)

FIGURE 19: REST OF WORLD INFECTIOUS LARYNGOTRACHEITIS DISEASE VACCINE MARKET, REGIONAL OUTLOOK, 2022 & 2032 (IN %)

FIGURE 20: LATIN AMERICA INFECTIOUS LARYNGOTRACHEITIS DISEASE VACCINE MARKET, 2023-2032 (IN $ MILLION)

FIGURE 21: MIDDLE EAST & AFRICA INFECTIOUS LARYNGOTRACHEITIS DISEASE VACCINE MARKET, 2023-2032 (IN $ MILLION)

FAQ’s

FAQs

Asia-Pacific is estimated to be the fastest-growing region in the global infectious laryngotracheitis disease vaccine market over the forecast period 2023 to 2032.

Mortality rates within the flock can fluctuate significantly, ranging from instances with no recorded deaths to situations where mortality reaches as high as 20%. The disease also has the potential to induce illness among birds, with symptoms persisting for a span that can extend from a few days to a couple of weeks.